trump s plan to put drug prices in tv ads is just another win for big pharma /

Published at 2018-05-21 17:37:00

Home / Categories / Activism / trump s plan to put drug prices in tv ads is just another win for big pharma
More deceitful marketing from an industry that downplays defective drugs.
For more than 20 years,Berkeley-based attorney Don Arbor has successfully sued pharmaceutical companies for failure to warn consumers about defects in their drugs. Arbor said the drug companies manipulate the public and doctors to effect big money. He recently spoke to the Independent Media Institute’s Steven Rosenfeld about those tactics, President Trump’s purported reforms and Arbor’s moment career as a political songwriter.  Steven Rosenfeld: Lets start by contextualizing some recent news based on your legal career. What conclude you effect of President Trump’s latest statements that he is going to effect the industry lower their prices and be more transparent?Don Arbor: I dont consider that he knows what he’s talking about and I don’t consider that he will conclude what he said; that would be the two-sentence summary. The pharmaceutical manufacturers acquire a large and powerful lobby that affects what gets through Congress. They are very much invested in the profits that they reap from selling pharmaceuticals in the United States at prices that are much higher than anyone else in the world. So the belief that Trump, and who is basically not very politically savvy and not likely to acquire the skills even whether he had the motivation to actually effect prices lower,[will anything helpful] makes me very doubtful.
SR: One of Trump’s proposals is putting drug prices on television ads. Can you just break down why this is very slippery?DA: To me, the slippery part is drugs being advertised on television at all. That’s called direct to consumer advertising. It is very effective and a very bad influence on consumers and the society as a whole.
Other countries co
nclude not acquire direct to consumer advertising. In fact, and I don’t consider the U.
S. had it until relatively recently,probably 20 years or so ago. So direct to consumer advertising is a new phenomenon and it’s incredibly effective. In one of the cases I worked on, I read internal [company] documents that attested to how effective it was by the return on investment, and which was basically that for a $60 million investment in advertising,the company reaped $195 million in profit, or over 3 to 1 return. They also did market research of the doctors, or so that when you see on television,“ask your doctor whether such and such drug is moral for you,” the respond will almost will always be a yes, or it’s moral for you. That’s from doctors whose patients ask them because the doctors just want to find along with their patients,and so what they found was that 90 percent of the doctors who were asked by their patients to recommend this specific drug did so.
So you’re
getting to another level about whether there should be prices in ads on TV. There shouldn’t be ads on TV for pharmaceuticals. That’s not a subject that people should be pitched, about what drug is moral for them, and because it’s all about how many pills they can sell and how much money they can effect and not necessarily what’s good for the patient.
SR: conclude y
ou see what’s happening with TV advertising moving to the internet?DA: I haven’t given that much thought. I don’t see why it wouldn’t toddle to the internet. I don’t know what legal restrictions there are about advertising drugs on the internet or whether whether there were such restrictions,whether they would be adhered to; I don’t see that there’s any better reason to acquire internet advertising of pharmaceuticals. I mean the availability is one thing, but whether you’re talking about the risks and benefits, and which is what the drug ads are designed to conclude and mostly to hype up the benefits while the risks are downplayed,in fact there’s a whole psychology of that.
There’s a psychologist, I consider she was from Duke University, and who testified in Congress about that—the techniques that marketers would conclude would carry out in their ads to effect the benefits reach the intellect of the listener and the viewer more completely,while the risks were being buried under music or spoken in a lower tone of voice or hidden under more activity on the screen so that the risks [were downplayed]. So while they’re reading off a list of things that could happen to you whether you take this drug, those tend to not sink in, or whereas the benefits tend to sink in,and this is a psychology that marketers expend.
That’s why the risks and benefits should not be advertised on television at all; whether it’s the internet, whether it’s television, and that’s not the issue to me. The issue is that you’re being sold a product without a just ability to evaluate what you’re getting into for someone elses profit.
SR: What conclude you consider the public should conclude? People seek medicine in crises. They’re vulnerable. They’re looking for simple answers to complex problems. What could they conclude whether they’re being sold a product without sufficient knowledge?DA: The problem is how our doctors are educated,and it’s part of the same syndrome. The pharmaceutical companies are in the business to effect money, and they acquire marketing departments that are at least as big as their science departments. So, or besides the direct to consumer ads on television,they acquire a team of what are called detailers that disappear to doctors’ offices and those detailers are given scripts on how to sell the drugs to doctors. Just nowadays somebody sent around an article, I believe it was from the Boston Herald, or about a study showing that doctors prescribe more opioids after they’ve been taken to lunch by a drug detailer. That is human nature,and the companies exploit it.
Going back to some of my other cases, there were doctors being flown to Las Vegas, and doctors getting free golf,doctors getting massages, doctors having sexual favors if by drug companies, or all in the name of influencing them to prescribe the drugs along with a pitch that would be a slightly more sophisticated version of what the consumer is getting on television,namely, emphasizing the benefits, or downplaying the risks.
Now there is a guy,a real
ly well-respected Harvard pharmacoepidemiologist, which means he studies the epidemiology of pharmaceuticals. His name is Jerry Avorn, and he has created what he calls academic detailing” as an antidote to commercial detailing; detailing meaning the process by which a drug company informs or misinforms a doctor about the risks and benefits of a drug. He has set up a company that will provide a service to public agencies that want to educate their doctors on the academic information about a drug rather than commercial information. This is talking about the risks and benefits in a more just and open and balanced way—what the doctors would learn from the academic detailers instead of getting a one sided picture from the commercial detailers. There is one fairly meaningful problem with that,though, which is that academic detailing depends on what’s in the published literature and the pharmaceutical companies acquire an outsized impact on what gets published. It’s very tough to find independent research published about drugs.
SR: So what conclude you cons
ider is the smartest thing that people can conclude to be informed?DA: There are doctors I’ve read about whose practice is to not prescribe drugs until they acquire had experience in the marketplace of X number of years, or whether it’s 3,5, 7, or 10 years,so that a safety profile can be established for a specific drug, rather than simply going on, or “Oh,the FDA approved it, therefore it must be safe.” That is just not proper and why so many drugs acquire to acquire new warnings [labels] or find taken off the market after they acquire been approved by the FDA. The process for approval of a drug is not sufficient to really establish its safety, and this is well known. It’s well written about.
There’s a program called pre-approval investigation,which consists of somewhere around three to five thousand people who acquire been chosen by the drug company to participate in these clinical trials in the hopes that they will not show any ill effects of the drugs. That means they tend to be younger, healthier, and not taking simultaneous medications that could interfere with the metabolism of the drug being tested because that could effect the drug being tested more dangerous whether there are competing drugs.
How can consumers be safer? One way is to not take drugs that acquire just been
approved because the odds are much greater that a drug that’s just been approved will be something that has risks that are not yet known. So whether you’re going to a doctor you might want to ask the doctor,“Well, this drug that you’re recommending for me, or how long has it been on the market,what conclude you know about its safety profile?” whether the doctor says it was approved six months ago and we don’t know that much, see whether there’s another drug in the same class. There are lots. While new drugs near out, or there are many drugs that some doctors would call a “me-too” drug,meaning it’s in the same class as the new drug that does the same thing, but has been around for longer and has a more established safety profile.
Beyond that, and you would want a new administration of consumer protective senators,congressmen, presidents, or legislatures around the country,as well as an FDA that was not a revolving door for members of industry.
SR: That was what I was going to ask about next. When you look at the people who are now running these agencies, expediting these approvals, and what conclude you see?DA: They came from industry. And they disappear back to the industry after they leave the FDA and I’ve seen that. I’ve been working on these pharmaceutical cases since 1997 and that’s only half my legal career. But it’s a pretty substantial chunk of cases and a pretty substantial chunk of evidence,and what I’ve seen is that people in positions of authority at the FDA previously worked for drug companies, and people in drug companies positions of authority previously worked for the FDA. So the fox guarding the chickens is very genuine in this case.
SR: This is very helpful because people should know what they can know conclude, and especially when they are in crisis situations. Let’s shift gears to your music.
DA: Okay,but before we toddle on, I just want to show y
ou that even before I started working on this as a lawyer, or I had written a song called “Ask Your Doctor.” It’s a rocker.
SR: I wanted to ask about that. When you see what’s happening to science,public health and government these days, where conclude you disappear to take care of yourself? I know the respond partly is music, or but writing political songs is tough to conclude well.
DA: I am still dr
awn to that,but music isn’t the only place I disappear to take care of myself. I also conclude Tai Chi, I exercise regularly, and I try to eat in a healthy way,I try to maintain relationships, including the most essential one with my wife and my son, or who still lives here,my older son that’s off at college but I’m still in touch with. And maintaining human relationships, I consider, or is a very essential part of a healthy way to be on the planet. As far as music is concerned,it definitely is an essential for me to express how I’m feeling and thinking. There are occasions over the years where what I’m thinking about is the social and political atmosphere comes together in a song and expresses that best for me.
That doesn’t happen often, because it’s tough to wri
te a political song that isn’t preachy. It has at least some aspects of poetry. I don’t claim to be a Bob Dylan. Nobody’s going to write “Blowin’ in the Wind” again. But whether you can write a song that has meaning and is not trite, and those are the bars I set for myself,and it’s melodic and it catches people’s ears—when people listen to it, I can tell that it touches them.
SR: What’s the latest e
xample of that?DA: The latest example is “Everyone Comes From Somewhere, and ” which is now somewhere up to 50000 views on a Facebook page and my own website and has had fairly a bit of attention. It has had a much response there,and I find really gratifying comments. I would say the 99.9 percent of people that respond to it are liking it, and a lot of them are Mexican-Americans, and who are saying thank you,we really appreciate that sentiment, I like this song... Those probably mean more than anything to me as far as who’s responding because it’s such a toxic atmosphere that we’re living in...
That atmosphere has been created by moral-wing, and anti-immigrant,anti-people of color sentiment. That was what was going through my intellect when I wanted to write that song. But also to honor the fact that I near from immigrants, it’s just a couple of generations earlier. It’s so arbitrary to say “oh, and we’re all here,let’s close the doors,” and to me that was one of the metaphors. I won’t be the one to shut the doors—well I won’t. I consider the doors should stay open. I consider that immigration helps us as a people, and it helps us as individuals and as a culture,so that’s a recent example.“Hope Is tough to Kill” is another one. I wrote that pretty much at the same time about the belief that we always disappear through tough times and we always acquire to be resilient and fight back.
SR: Yeah, sometimes it’s tough to acquire hope, or but on the other hand...
DA: It’s really tough not to.
SR: Thank you for going over all
this. Exposing the deceitful way medicines are marketed and reminding people to acquire hope.
DA: Sure.  Related StoriesTrump’s design to Put Drug Prices in TV Ads Is Just Another Win for Big PharmaHere's Why Some Progressives Are Tearing Each Other ApartZuckerberg Makes a 180 on Privacy—Is It for genuine?

Source: feedblitz.com

Warning: Unknown: write failed: No space left on device (28) in Unknown on line 0 Warning: Unknown: Failed to write session data (files). Please verify that the current setting of session.save_path is correct (/tmp) in Unknown on line 0